Insight Molecular Diagnostics (IMDX) EBT Margin (2020 - 2026)
Insight Molecular Diagnostics (IMDX) posted EBT Margin of 35131.25% for Q1 2026, down 1583.83% sequentially from 2086.39% in Q4 2025, and down 3476539.0% YoY from N/an in Q1 2025.
Insight Molecular Diagnostics (IMDX) EBT Margin (2020 - 2026) Analysis & Trends
Insight Molecular Diagnostics has reported EBT Margin for 7 years, with the latest figure at 35131.25% in Q1 2026.
- Quarterly EBT Margin fell 3476539.0% year-over-year to 35131.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2621.34% (down 116915.0% YoY) and the FY2025 annual result came in at 1471.29%, up 519947.0% from the prior year.
- EBT Margin declined to 35131.25% in Q1 2026 per IMDX's latest filing, from 2086.39% in the prior quarter.
- Over five years, EBT Margin peaked at 2006.4% in Q1 2023 and troughed at 35131.25% in Q1 2026.
- A 5-year average of 4274.16% and a median of 2086.39% in 2025 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2025 and 2026: EBT Margin soared 482108 bps in 2025, then slumped 3476539 bps in 2026.
- Over 5 years, EBT Margin stood at 301.25% in 2022, then plunged by 1591 bps to 5092.99% in 2023, then surged by 55 bps to 2281.7% in 2024, then grew by 9 bps to 2086.39% in 2025, then slumped by 1584 bps to 35131.25% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 35131.25%, 2086.39%, and 2943.85% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 16.04% |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 17.21% |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | -8.93% |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 22.23% |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 6.89% |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 34.29% |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | 22.43% |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 28.17% |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 10.36% |
| 10 | Insight Molecular Diagnostics | 158.03 Mn | 139.50 Mn | 157,000.00 | -4,770.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4,770.71% |
| Mar 31, 2026 | -28,390.63% |
| Dec 31, 2025 | -2,057.51% |
| Sep 30, 2025 | -4,249.23% |
| Jun 30, 2025 | -1,900.00% |
| Mar 31, 2025 | -318.01% |
| Dec 31, 2024 | -2,262.92% |
| Sep 30, 2024 | -11,752.17% |
| Jun 30, 2024 | -4,760.58% |
| Mar 31, 2024 | -5,186.93% |
| Dec 31, 2023 | -5,092.99% |
| Sep 30, 2023 | -1,512.59% |
| Jun 30, 2023 | -1,799.78% |
| Mar 31, 2023 | 2,006.40% |
| Dec 31, 2022 | -1,415.43% |
| Sep 30, 2022 | -191.37% |
| Jun 30, 2022 | -74.54% |
| Mar 31, 2022 | -326.92% |
| Dec 31, 2021 | -997.16% |
| Sep 30, 2021 | -1,402.44% |